Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Feb;36(2):562-565.
doi: 10.1038/s41375-021-01500-1. Epub 2021 Dec 22.

SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia

Sibylle C Mellinghoff  1   2   3 , Sandra Robrecht  4 , Leonie Mayer  5   6   7 , Leonie M Weskamm  5   6   7 , Christine Dahlke  5   6   7 , Henning Gruell  8 , Kanika Vanshylla  8 , Hans A Schlösser  9 , Martin Thelen  9 , Anna-Maria Fink  4 , Kirsten Fischer  4 , Florian Klein  8 , Marylyn M Addo  5   6   7 , Barbara Eichhorst  4 , Michael Hallek  4 , Petra Langerbeins  4
Affiliations
Comment

SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia

Sibylle C Mellinghoff et al. Leukemia. 2022 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

SCM reports grants from DZIF (Clinical Leave Stipend). AMF reports research funding from Celgene/Bristol Myers Squibb (Inst), AstraZeneca (Inst), and travel Expenses by AbbVie. KF reports other from Roche, other from AbbVie. BE reports grants and personal fees from Janssen-Cilag, grants and personal fees from Roche, personal fees from Novartis, grants and personal fees from AbbVie, personal fees from Celgene, personal fees from ArQule, personal fees from AstraZeneca, personal fees from Oxford Biomedica (UK), grants and personal fees from Gilead, grants from BeiGene, outside the submitted work. MH reports other from AbbVie, other from F. Hoffman-LaRoche, other from Gilead, other from Janssen-Cilag, other from Mundipharma, during the conduct of the study. PL reports grants and personal fees from Janssen-Cilag, personal fees from Abbvie, other from F. Hoffman-LaRoche, personal fees from AstraZeneca. The remaining authors declare no competing financial interests for this study.

Figures

Fig. 1
Fig. 1. Humoral and T cell immune responses after COVID-19 vaccination.
A SARS-CoV-2 RBD specific IgG in CLL patients (median 889.9 BAU/ml, IQR 80.2-2127.4, for responders) and healthy controls (median 1839.8 BAU/ml, IQR 647.0-2583.4) measured by ELISA. B Antibody response rate in CLL patients and healthy volunteers. *p = 0.001. C Serum neutralizing activity (50% inhibitory serum dilution) determined in a pseudovirus neutralizing assay against the Wu-01 pseudovirus strain. Bars indicating geometric mean ID50 with 95% confidence intervals. A dashed line indicates limit of detection [10]. Samples with no detectable neutralization (ID50 < 10) were plotted with an arbitrary ID50 of 5 for graphical representation. Dashed line in the CLL group shows geometric mean ID50 for individuals with a detectable neutralizing response. D Interferon-y T cell ELISpot response in CLL patients and HC. Shown values are mean spots in peptide-stimulated wells minus background in negative control wells. Error bars represent median ± interquartile range. The dotted line indicates the positive threshold of 48 SFC/106 PBMC. Samples were acquired 35 days after the second vaccination in HC and at a median of 47 days after second vaccination in CLL patients. Two patients had much higher correlated of T cell immunity after vaccination: One was vaccinated thrice and one was the only patient of the entire cohort that had received heterologous prime-boost immunization with BNT162b and ChAdOx1. BNT BNT162b, ChAd ChAdOx1, HC Healthy Control.
See this image and copyright information in PMC

Comment on

  • COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study.
    Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, Andres M, Antic D, Baile M, Baliakas P, Bron D, Capasso A, Chatzileontiadou S, Cordoba R, Correa JG, Cuéllar-García C, De Paoli L, De Paolis MR, Del Poeta G, Demosthenous C, Dimou M, Donaldson D, Doubek M, Efstathopoulou M, Eichhorst B, El-Ashwah S, Enrico A, Espinet B, Farina L, Ferrari A, Foglietta M, Frederiksen H, Fürstenau M, García-Marco JA, García-Serra R, Gentile M, Gimeno E, Glenthøj A, Gomes da Silva M, Gutwein O, Hakobyan YK, Herishanu Y, Hernández-Rivas JÁ, Herold T, Innocenti I, Itchaki G, Jaksic O, Janssens A, Kalashnikova ОB, Kalicińska E, Karlsson LK, Kater AP, Kersting S, Labrador J, Lad D, Laurenti L, Levin MD, Lista E, Lopez-Garcia A, Malerba L, Marasca R, Marchetti M, Marquet J, Mattsson M, Mauro FR, Milosevic I, Mirás F, Morawska M, Motta M, Munir T, Murru R, Niemann CU, Rodrigues RN, Olivieri J, Orsucci L, Papaioannou M, Pavlovsky MA, Piskunova I, Popov VM, Quaglia FM, Quaresmini G, Qvist K, Reda G, Rigolin GM, Ruchlemer R, Saghumyan G, Shrestha A, Šimkovič M, Špaček M, Sportoletti P, Stanca O, Stavroyianni N, Tadmor T, Te Raa D, Tonino SH, Trentin L, Van Der Spek E, van Gel… See abstract for full author list ➔ Chatzikonstantinou T, et al. Leukemia. 2021 Dec;35(12):3444-3454. doi: 10.1038/s41375-021-01450-8. Epub 2021 Nov 1. Leukemia. 2021. PMID: 34725454 Free PMC article.

References

    1. Chatzikonstantinou T, Kapetanakis A, Scarfò L, Karakatsoulis G, Allsup D, Cabrero AA, et al. COVID-19 severity and mortality in patients with CLL: An update of the international ERIC and Campus CLL study. Leukemia. 2021;35:3444–54. doi: 10.1038/s41375-021-01450-8. - DOI - PMC - PubMed
    1. Koch T, Mellinghoff SC, Shamsrizi P, Addo MM, Dahlke C. Correlates of vaccine-induced protection against SARS-CoV-2. Vaccines. 2021;9:238. doi: 10.3390/vaccines9030238. - DOI - PMC - PubMed
    1. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020;587:270–4. doi: 10.1038/s41586-020-2598-9. - DOI - PubMed
    1. Benjamini O, Rokach L, Itchaki G, Braester A, Shvidel L, Goldschmidt N, et al. Safety and efficacy of BNT162b mRNA Covid19 Vaccine in patients with chronic lymphocytic leukemia. Haematologica. 2021. 10.3324/haematol.2021.279196. Epub ahead of print. - PubMed
    1. Herishanu Y, Avivi I, Aharon A, Shefer G, Levi S, Bronstein Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137:3165–73. doi: 10.1182/blood.2021011568. - DOI - PMC - PubMed

Publication types

Substances